PAZEC: a Dutch Gynaecological Oncology Group open-label, multicenter, phase II study of pazopanib in metastatic and locally advanced hormone-resistant endometrial cancer.
Anneke M WestermannPetronella OttevangerAn ReynersJudith R KroepMartijn G H Van OijenRoy I LalisangPetronella O WitteveenPublished in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2024)
Pazopanib met its primary endpoint of 3 months' progression-free survival in advanced endometrial cancer (63.3%), but response rates were modest. There may be a correlation for rare but severe gastrointestinal toxicity with previous treatments and/or disease site that has yet to be elucidated.
Keyphrases
- endometrial cancer
- phase ii study
- locally advanced
- free survival
- open label
- squamous cell carcinoma
- rectal cancer
- neoadjuvant chemotherapy
- radiation therapy
- metastatic renal cell carcinoma
- palliative care
- small cell lung cancer
- clinical trial
- phase ii
- phase iii
- oxidative stress
- early onset
- tyrosine kinase
- study protocol
- randomized controlled trial
- drug induced